Current status of immunological therapies for prostate cancer.
about
Immunobiology and immunotherapy in genitourinary malignanciesCombining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapyTherapeutic cancer vaccines: past, present, and futureCD4 T-Cell-mediated immune response to prostatic proteins in HLA-DRB1*1503 transgenic mice and identification of a novel HLA-DRB1*1503-restricted T-cell epitope from human prostatic acid phosphatase.In vivo trafficking and immunostimulatory potential of an intranasally-administered primary dendritic cell-based vaccine.PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.Prostate cancer as a model for tumour immunotherapy.Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer.MyD88/CD40 Genetic Adjuvant Function in Cutaneous Atypical Antigen-Presenting Cells Contributes to DNA Vaccine ImmunogenicityManagement of metastatic castration-resistant prostate cancerA phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors.Immunotherapy and immune evasion in prostate cancer.Emerging roles of human prostatic Acid phosphataseSipuleucel-T: immunotherapy for advanced prostate cancer.Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms.The role of chemotherapy and new targeted agents in the management of primary prostate cancer.Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines.Sipuleucel-T in patients with metastatic castration-resistant prostate cancer: an insight for oncologists.Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy.Unmasking the immune recognition of prostate cancer with CTLA4 blockade.The unfolding treatment landscape for men with castration-resistant prostate cancer.Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer.Oncolytic virus-initiated protective immunity against prostate cancer
P2860
Q26738668-5112DD72-23E9-47E7-9160-4AB184948B56Q26851608-1B5E1047-582B-46BC-B072-BA25243128F9Q26863283-D363E21C-B63E-4801-9351-7FFBFFBF4A85Q33707921-999DD9D2-6CFB-482C-9067-323019B28766Q33767127-6C365464-1480-438D-9939-6AA5C3858B50Q34644359-62D6DD4D-FEE7-4609-8A7E-0EC307D3EF68Q34856875-A06C33BA-BA95-4585-A001-A15BBA7F6B59Q34906723-AD3A4A13-E40D-4775-AAB2-0F1EADF2CB5BQ36163830-285F3AF5-7D2D-46A9-B41A-32DED591E289Q36936267-05621A3C-D1F2-44AD-9925-906F5C178A23Q37007590-7A7E10F9-1D54-42D1-ADF5-EEB9BB651EE5Q37061769-62D9DC98-3FCE-4F58-A265-EA5CE5924C6CQ37145460-1BEBF19E-C9FC-48EF-8F07-A31F1602482AQ37283724-21B75C1E-DCF0-49D2-8A6C-5C744EC2C6CFQ37459636-6CF21D2F-AB4A-45B0-95A4-D106AE6DD4B7Q37708171-3FB392A8-9131-4A0D-8038-246428097739Q37873932-496AC28F-72BF-48F7-9C54-687919D9903CQ37905606-EF64DDE6-CE8C-417A-9F8B-DD7DFD1B5CA1Q37983730-24BC9C92-29CC-4349-AC20-20B93727959CQ37989393-D52049DC-263E-4437-9A8B-B8071B14D9DBQ38056914-ED16B6C7-FF9B-43B5-8D31-ADFE929E26A5Q39525614-685BD909-94F8-4244-98C8-0936918B7CFDQ39589931-792A1654-81B4-416E-AA90-72F4E1B4ADE3Q39606073-4F0ADA60-7051-4BED-BB67-3A0B231C812F
P2860
Current status of immunological therapies for prostate cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Current status of immunological therapies for prostate cancer.
@en
Current status of immunological therapies for prostate cancer.
@nl
type
label
Current status of immunological therapies for prostate cancer.
@en
Current status of immunological therapies for prostate cancer.
@nl
prefLabel
Current status of immunological therapies for prostate cancer.
@en
Current status of immunological therapies for prostate cancer.
@nl
P2860
P1476
Current status of immunological therapies for prostate cancer
@en
P2093
Charles G Drake
P2860
P304
P356
10.1097/MOU.0B013E3283381793
P577
2010-05-01T00:00:00Z